Non-Billable / Non-Specific Code
ICD-10-CM D60 is the diagnosis code for Acquired pure red cell aplasia [erythroblastopenia]. This code falls under the section "Aplastic and other anemias and other bone marrow failure syndromes" within Chapter 3 — Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89). It is a non-billable/non-specific ICD-10-CM code that should not be used for reimbursement. A more specific sub-code is required for billing. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
The following conditions should never be coded at the same time as D60. They are mutually exclusive:
Understanding where D60 sits in the ICD-10-CM classification helps ensure proper coding:
No, D60 is a non-billable/non-specific code. You should use a more specific sub-code for billing and reimbursement.
D60 is the ICD-10-CM diagnosis code for "Acquired pure red cell aplasia [erythroblastopenia]". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
D60 is located in Section D60-D64 — "Aplastic and other anemias and other bone marrow failure syndromes" within Chapter 3 of the ICD-10-CM Tabular List.
D60 has 4 sub-code(s) that provide more specific detail: D60.0, D60.1, D60.8, D60.9.
Use D60 when the patients documented diagnosis matches "Acquired pure red cell aplasia [erythroblastopenia]" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Acquired pure red cell aplasia [erythroblastopenia] is D60.
No, D60 is non-billable. Use a more specific sub-code for primary diagnosis billing.
D60 is in Chapter 3 of the ICD-10-CM Tabular List.
Type 1 Excludes for D60 include: congenital red cell aplasia (D61.01).
Yes, D60 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.